Products
Dalnicastobart Biosimilar Monoclonal Antibody (CD40) for Research
Cat No.: GMP-Bios-INN-1149
Anti-TNFRSF5/CD40 therapeutic antibody (Pre-made Dalnicastobart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Dalnicastobart (development code LVGN-7409) is a monoclonal antibody targeting CD40. It is developed by MD Anderson Cancer Center and Lyvgen Biopharma for cancer, gastric cancer, head and neck cancer among others. It is in Phase I clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1149-1mg | 1mg | 3090 |
| GMP-Bios-INN-1149-10mg | 10mg | |
| GMP-Bios-INN-1149-100mg | 100mg | |
| GMP-Bios-INN-1149-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Dalnicastobart biosimilar, Whole mAb, Anti-TNFRSF5/CD40 Antibody: Anti-CD40/Tumor necrosis factor receptor superfamily member 5/B-cell surface antigen CD40/Bp50 therapeutic antibody |
| INN Name | Dalnicastobart |
| Target | TNFRSF5/CD40 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2023 |
| Companies | MD Anderson Cancer Center;Lyvgen Biopharma |
| Conditions Approved | na |
| Conditions Active | Cancer;Gastric cancer;Head and neck cancer;Esophageal;Hepatocellular carcinoma;Metastatic cancer |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
